{"id":"https://openalex.org/W4313367299","doi":"https://doi.org/10.1016/j.yrtph.2022.105329","title":"Re-evaluating the need for chronic toxicity studies with therapeutic monoclonal antibodies, using a weight of evidence approach","display_name":"Re-evaluating the need for chronic toxicity studies with therapeutic monoclonal antibodies, using a weight of evidence approach","publication_year":2022,"publication_date":"2022-12-30","ids":{"openalex":"https://openalex.org/W4313367299","doi":"https://doi.org/10.1016/j.yrtph.2022.105329","pmid":"https://pubmed.ncbi.nlm.nih.gov/36592682"},"language":"en","primary_location":{"id":"doi:10.1016/j.yrtph.2022.105329","doi":"https://doi.org/10.1016/j.yrtph.2022.105329","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.yrtph.2022.105329","pdf_url":null,"source":{"id":"https://openalex.org/S87719511","display_name":"Regulatory Toxicology and Pharmacology","issn_l":"0273-2300","issn":["0273-2300","1096-0295"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","jufo-1","medline","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regulatory Toxicology and Pharmacology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://doi.org/10.1016/j.yrtph.2022.105329","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5074370904","display_name":"Hsiao-Tzu Chien","orcid":"https://orcid.org/0000-0002-3761-8993","observed_orcids":["https://orcid.org/0000-0002-3761-8993"]},"institutions":[{"id":"https://openalex.org/I2802934949","display_name":"Radboud University Medical Center","ror":"https://ror.org/05wg1m734","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2802934949"]},{"id":"https://openalex.org/I4210150351","display_name":"Medicines Evaluation Board","ror":"https://ror.org/05mv4rb84","country_code":"NL","type":"education","lineage":["https://openalex.org/I4210150351"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Hsiao-Tzu Chien","raw_affiliation_strings":["Medicines Evaluation Board, Utrecht, the Netherlands; Radboud University Medical Center, Nijmegen, the Netherlands","Medicines Evaluation Board, Utrecht, the Netherlands","Radboud University Medical Center, Nijmegen, the Netherlands"],"raw_orcid":"https://orcid.org/0000-0002-3761-8993","affiliations":[{"raw_affiliation_string":"Medicines Evaluation Board, Utrecht, the Netherlands; Radboud University Medical Center, Nijmegen, the Netherlands","institution_ids":["https://openalex.org/I2802934949","https://openalex.org/I4210150351"]},{"raw_affiliation_string":"Medicines Evaluation Board, Utrecht, the Netherlands","institution_ids":["https://openalex.org/I4210150351"]},{"raw_affiliation_string":"Radboud University Medical Center, Nijmegen, the Netherlands","institution_ids":["https://openalex.org/I2802934949"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013572549","display_name":"Helen M. Prior","orcid":"https://orcid.org/0000-0002-8700-7226","observed_orcids":["https://orcid.org/0000-0002-8700-7226"]},"institutions":[{"id":"https://openalex.org/I4210136630","display_name":"National Centre for the Replacement Refinement and Reduction of Animals in Research","ror":"https://ror.org/02w0kg036","country_code":"GB","type":"other","lineage":["https://openalex.org/I4210136630"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Helen Prior","raw_affiliation_strings":["National Centre for the Replacement Refinement & Reduction of Animals in Research (NC3Rs), London, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"National Centre for the Replacement Refinement & Reduction of Animals in Research (NC3Rs), London, UK","institution_ids":["https://openalex.org/I4210136630"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110993839","display_name":"Laura Andrews","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2948539688","display_name":"AbbVie (United States)","ror":"https://ror.org/02g5p4n58","country_code":"US","type":"company","lineage":["https://openalex.org/I2948539688"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Laura Andrews","raw_affiliation_strings":["AbbVie, Worcester, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AbbVie, Worcester, MA, USA","institution_ids":["https://openalex.org/I2948539688"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035530012","display_name":"Leon van Aerts","orcid":"https://orcid.org/0000-0002-0025-0099","observed_orcids":["https://orcid.org/0000-0002-0025-0099"]},"institutions":[{"id":"https://openalex.org/I4210150351","display_name":"Medicines Evaluation Board","ror":"https://ror.org/05mv4rb84","country_code":"NL","type":"education","lineage":["https://openalex.org/I4210150351"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Leon van Aerts","raw_affiliation_strings":["Medicines Evaluation Board, Utrecht, the Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medicines Evaluation Board, Utrecht, the Netherlands","institution_ids":["https://openalex.org/I4210150351"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059637817","display_name":"Annick J. Cauvin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I85722119","display_name":"UCB Pharma (Belgium)","ror":"https://ror.org/01n029866","country_code":"BE","type":"company","lineage":["https://openalex.org/I85722119"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Annick Cauvin","raw_affiliation_strings":["UCB BioPharma, Brussels, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCB BioPharma, Brussels, Belgium","institution_ids":["https://openalex.org/I85722119"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103398339","display_name":"David O. Clarke","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David O. Clarke","raw_affiliation_strings":["Lilly Corporate Center, Indianapolis, IN, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly Corporate Center, Indianapolis, IN, USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061769563","display_name":"Kaushik Datta","orcid":"https://orcid.org/0000-0002-5967-0434","observed_orcids":["https://orcid.org/0000-0002-5967-0434"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kaushik Datta","raw_affiliation_strings":["Bristol Myers Squibb, Nonclinical Research and Development, New Jersey, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol Myers Squibb, Nonclinical Research and Development, New Jersey, USA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015954706","display_name":"Maggie Dempster","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Maggie Dempster","raw_affiliation_strings":["GlaxoSmithKline, King of Prussia, PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, King of Prussia, PA, USA","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028549245","display_name":"Noel O. Dybdal","orcid":"https://orcid.org/0000-0003-4764-6020","observed_orcids":["https://orcid.org/0000-0003-4764-6020"]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Noel Dybdal","raw_affiliation_strings":["Genentech, South San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genentech, South San Francisco, CA, USA","institution_ids":["https://openalex.org/I183934855"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029895437","display_name":"Wendy Jo Freebern","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Wendy Freebern","raw_affiliation_strings":["Janssen Inc., Spring House, PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Inc., Spring House, PA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053507694","display_name":"Lolke de Haan","orcid":"https://orcid.org/0000-0002-2201-293X","observed_orcids":["https://orcid.org/0000-0002-2201-293X"]},"institutions":[{"id":"https://openalex.org/I47508984","display_name":"Imperial College London","ror":"https://ror.org/041kmwe10","country_code":"GB","type":"education","lineage":["https://openalex.org/I47508984"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Lolke de Haan","raw_affiliation_strings":["ADC Therapeutics, I-HUB, Imperial College White City Campus, London, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ADC Therapeutics, I-HUB, Imperial College White City Campus, London, UK","institution_ids":["https://openalex.org/I47508984"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Danuta Herzyk","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Danuta Herzyk","raw_affiliation_strings":["Merck & Co., Inc., West Point, PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc., West Point, PA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029550004","display_name":"Adam Hey","orcid":"https://orcid.org/0000-0002-8982-3219","observed_orcids":["https://orcid.org/0000-0002-8982-3219"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Adam Hey","raw_affiliation_strings":["AstraZeneca, Cambridge, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca, Cambridge, UK","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044450344","display_name":"Thomas Kissner","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210138838","display_name":"Sanofi (Germany)","ror":"https://ror.org/03ytdtb31","country_code":"DE","type":"company","lineage":["https://openalex.org/I3018075036","https://openalex.org/I4210138838"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Thomas Kissner","raw_affiliation_strings":["Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany","institution_ids":["https://openalex.org/I4210138838"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002871553","display_name":"Sven Kronenberg","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Sven Kronenberg","raw_affiliation_strings":["Roche Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Roche Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009031195","display_name":"Michael W. Leach","orcid":"https://orcid.org/0009-0001-6023-2634","observed_orcids":["https://orcid.org/0009-0001-6023-2634"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael W. Leach","raw_affiliation_strings":["Pfizer Inc., Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc., Cambridge, MA, USA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086337098","display_name":"Donna Lee","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Donna Lee","raw_affiliation_strings":["Genentech, South San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genentech, South San Francisco, CA, USA","institution_ids":["https://openalex.org/I183934855"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021907635","display_name":"Katrin Sch\u00fctte","orcid":"https://orcid.org/0000-0001-6007-8385","observed_orcids":["https://orcid.org/0000-0001-6007-8385"]},"institutions":[{"id":"https://openalex.org/I2800387288","display_name":"European Commission","ror":"https://ror.org/00k4n6c32","country_code":"BE","type":"government","lineage":["https://openalex.org/I1320481043","https://openalex.org/I2800387288"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Katrin Schutte","raw_affiliation_strings":["European Commission, Brussels, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"European Commission, Brussels, Belgium","institution_ids":["https://openalex.org/I2800387288"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088593926","display_name":"Fiona R. Sewell","orcid":"https://orcid.org/0000-0001-5589-9453","observed_orcids":["https://orcid.org/0000-0001-5589-9453"]},"institutions":[{"id":"https://openalex.org/I4210136630","display_name":"National Centre for the Replacement Refinement and Reduction of Animals in Research","ror":"https://ror.org/02w0kg036","country_code":"GB","type":"other","lineage":["https://openalex.org/I4210136630"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Fiona Sewell","raw_affiliation_strings":["National Centre for the Replacement Refinement & Reduction of Animals in Research (NC3Rs), London, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"National Centre for the Replacement Refinement & Reduction of Animals in Research (NC3Rs), London, UK","institution_ids":["https://openalex.org/I4210136630"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007993601","display_name":"Kevin Trouba","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kevin Trouba","raw_affiliation_strings":["Janssen Inc., Spring House, PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Inc., Spring House, PA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111459181","display_name":"Peter C. Ulrich","orcid":"https://orcid.org/0000-0001-6672-2223","observed_orcids":["https://orcid.org/0000-0001-6672-2223"]},"institutions":[{"id":"https://openalex.org/I4400600974","display_name":"Novartis Institutes for BioMedical Research","ror":"https://ror.org/053gv2m95","country_code":"CH","type":"funder","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4400600974"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Peter Ulrich","raw_affiliation_strings":["Novartis Institutes for BioMedical Research, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Institutes for BioMedical Research, Basel, Switzerland","institution_ids":["https://openalex.org/I4400600974"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077876000","display_name":"Lucinda R. Weir","orcid":"https://orcid.org/0000-0002-3563-6100","observed_orcids":["https://orcid.org/0000-0002-3563-6100"]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Lucinda Weir","raw_affiliation_strings":["GlaxoSmithKline, Ware, Hertfordshire, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Ware, Hertfordshire, UK","institution_ids":["https://openalex.org/I188950975"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5112451436","display_name":"Peter J.K. van Meer","orcid":"https://orcid.org/0000-0001-6493-1697","observed_orcids":["https://orcid.org/0000-0001-6493-1697"]},"institutions":[{"id":"https://openalex.org/I4210150351","display_name":"Medicines Evaluation Board","ror":"https://ror.org/05mv4rb84","country_code":"NL","type":"education","lineage":["https://openalex.org/I4210150351"]}],"countries":["NL"],"is_corresponding":true,"raw_author_name":"Peter van Meer","raw_affiliation_strings":["Medicines Evaluation Board, Utrecht, the Netherlands. Electronic address: p.v.meer@cbg-meb.nl","Medicines Evaluation Board, Utrecht, the Netherlands"],"raw_orcid":"https://orcid.org/0000-0001-6493-1697","affiliations":[{"raw_affiliation_string":"Medicines Evaluation Board, Utrecht, the Netherlands. Electronic address: p.v.meer@cbg-meb.nl","institution_ids":["https://openalex.org/I4210150351"]},{"raw_affiliation_string":"Medicines Evaluation Board, Utrecht, the Netherlands","institution_ids":["https://openalex.org/I4210150351"]}]}],"institutions":[],"countries_distinct_count":6,"institutions_distinct_count":17,"corresponding_author_ids":["https://openalex.org/A5112451436"],"corresponding_institution_ids":["https://openalex.org/I4210150351"],"apc_list":{"value":3800,"currency":"USD","value_usd":3800},"apc_paid":{"value":3800,"currency":"USD","value_usd":3800},"fwci":1.9714,"has_fulltext":true,"cited_by_count":36,"citation_normalized_percentile":{"value":0.87421206,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":96,"max":100},"biblio":{"volume":"138","issue":null,"first_page":"105329","last_page":"105329"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T14072","display_name":"Immunotoxicology and immune responses","score":0.48170000314712524,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T14072","display_name":"Immunotoxicology and immune responses","score":0.48170000314712524,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.20720000565052032,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12281","display_name":"Animal testing and alternatives","score":0.20069999992847443,"subfield":{"id":"https://openalex.org/subfields/3404","display_name":"Small Animals"},"field":{"id":"https://openalex.org/fields/34","display_name":"Veterinary"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/therapeutic-monoclonal-antibodies","display_name":"therapeutic monoclonal antibodies","score":0.8880000114440918},{"id":"https://openalex.org/keywords/weight-of-evidence","display_name":"weight of evidence","score":0.7889999747276306},{"id":"https://openalex.org/keywords/long-term-safety","display_name":"long-term safety","score":0.796999990940094},{"id":"https://openalex.org/keywords/first-in-human-study","display_name":"first-in-human study","score":0.7879999876022339},{"id":"https://openalex.org/keywords/reduction-of-animal-use","display_name":"animal use reduction","score":0.7570000290870667},{"id":"https://openalex.org/keywords/study-design-optimization","display_name":"study design optimization","score":0.6899999976158142},{"id":"https://openalex.org/keywords/regulatory-toxicology","display_name":"regulatory toxicology","score":0.42800000309944153},{"id":"https://openalex.org/keywords/drug-registration","display_name":"drug registration","score":0.3840000033378601}],"concepts":[{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.8755453824996948},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.7509403228759766},{"id":"https://openalex.org/C53164099","wikidata":"https://www.wikidata.org/wiki/Q5114007","display_name":"Chronic toxicity","level":3,"score":0.6049489974975586},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5209404230117798},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.5061325430870056},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.48809540271759033},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.47064298391342163},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.3404858708381653},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.25724032521247864},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.20002061128616333}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012107","descriptor_name":"Research Design","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true}],"locations_count":4,"locations":[{"id":"doi:10.1016/j.yrtph.2022.105329","doi":"https://doi.org/10.1016/j.yrtph.2022.105329","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.yrtph.2022.105329","pdf_url":null,"source":{"id":"https://openalex.org/S87719511","display_name":"Regulatory Toxicology and Pharmacology","issn_l":"0273-2300","issn":["0273-2300","1096-0295"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","jufo-1","medline","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regulatory Toxicology and Pharmacology","raw_type":"journal-article"},{"id":"pmid:36592682","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/36592682","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regulatory toxicology and pharmacology : RTP","raw_type":"Journal Article"},{"id":"pmh:oai:repository.ubn.ru.nl:2066/290916","doi":null,"is_oa":true,"landing_page_url":"https://repository.ubn.ru.nl/handle/2066/290916","pdf_url":"https://repository.ubn.ru.nl//bitstream/handle/2066/290916/290916.pdf","source":{"id":"https://openalex.org/S4306401067","display_name":"Radboud Repository (Radboud University)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I145872427","host_organization_name":"Radboud University Nijmegen","host_organization_lineage":["https://openalex.org/I145872427"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Regulatory Toxicology and Pharmacology, 138","raw_type":"Article / Letter to editor"},{"id":"pmh:ru:oai:repository.ubn.ru.nl:2066/290916","doi":null,"is_oa":true,"landing_page_url":"http://hdl.handle.net/2066/290916","pdf_url":null,"source":{"id":"https://openalex.org/S4306401067","display_name":"Radboud Repository (Radboud University)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I145872427","host_organization_name":"Radboud University Nijmegen","host_organization_lineage":["https://openalex.org/I145872427"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Regulatory Toxicology and Pharmacology, 138","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":{"id":"doi:10.1016/j.yrtph.2022.105329","doi":"https://doi.org/10.1016/j.yrtph.2022.105329","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.yrtph.2022.105329","pdf_url":null,"source":{"id":"https://openalex.org/S87719511","display_name":"Regulatory Toxicology and Pharmacology","issn_l":"0273-2300","issn":["0273-2300","1096-0295"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","jufo-1","medline","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regulatory Toxicology and Pharmacology","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.9789000153541565,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320314178","display_name":"European Federation of Pharmaceutical Industries and Associations","ror":"https://ror.org/00g1x4v36"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4313367299.pdf","grobid_xml":"https://content.openalex.org/works/W4313367299.grobid-xml"},"referenced_works_count":23,"referenced_works":["https://openalex.org/W1516645853","https://openalex.org/W1970942128","https://openalex.org/W2013758511","https://openalex.org/W2031622860","https://openalex.org/W2034773742","https://openalex.org/W2044692977","https://openalex.org/W2076692468","https://openalex.org/W2134240536","https://openalex.org/W2146127535","https://openalex.org/W2152603557","https://openalex.org/W2344371104","https://openalex.org/W2624920479","https://openalex.org/W2901866188","https://openalex.org/W3010214560","https://openalex.org/W3017518709","https://openalex.org/W3047159034","https://openalex.org/W3126123443","https://openalex.org/W3159662538","https://openalex.org/W3161493494","https://openalex.org/W3196422877","https://openalex.org/W4224099495","https://openalex.org/W4316126909","https://openalex.org/W6776338799"],"related_works":["https://openalex.org/W4399264491","https://openalex.org/W7154623627","https://openalex.org/W7067448850","https://openalex.org/W7160273715","https://openalex.org/W2076692468","https://openalex.org/W4401161248","https://openalex.org/W1588640410","https://openalex.org/W4402839163","https://openalex.org/W1978933603","https://openalex.org/W2032160423"],"abstract_inverted_index":{"To":[0],"support":[1,171],"registration":[2,176],"of":[3,55,88,108,123],"monoclonal":[4],"antibodies":[5],"(mAbs)":[6],"for":[7,30,67,111,148,177],"chronic":[8,62,99],"indications,":[9],"6-month":[10,45],"toxicity":[11,35,46,63,153,165],"studies":[12,64,100,166],"have":[13],"historically":[14],"been":[15],"conducted.":[16],"Experience":[17],"with":[18,33,125],"mAb":[19,150],"development":[20,174],"has":[21],"shown":[22],"a":[23,44,149],"relatively":[24],"benign":[25],"and":[26,61,130,175],"well-understood":[27],"safety":[28,54,113],"profile":[29],"this":[31],"class,":[32],"most":[34],"findings":[36],"anticipated":[37],"based":[38],"on":[39,58],"pharmacology.":[40],"We":[41],"evaluated":[42],"whether":[43],"study":[47,78,104],"is":[48],"necessary":[49],"to":[50,75,80,102,133,151,170],"assess":[51],"the":[52,145],"long-term":[53],"mAbs.":[56,179],"Data":[57],"First-in-Human":[59],"(FIH)-enabling":[60],"were":[65,84,96,119],"shared":[66],"142":[68],"mAbs":[69],"submitted":[70],"by":[71],"11":[72],"companies.":[73],"Opportunities":[74],"further":[76],"optimize":[77],"designs":[79],"reduce":[81],"animal":[82],"usage":[83],"identified.":[85],"For":[86],"71%":[87],"mAbs,":[89],"no":[90,93],"toxicities":[91,95,107],"or":[92,114],"new":[94],"noted":[97],"in":[98,121],"compared":[101],"FIH-enabling":[103],"findings.":[105],"New":[106],"potential":[109],"concern":[110],"human":[112],"that":[115,143],"changed":[116],"trial":[117],"design":[118],"identified":[120],"13.5%":[122],"cases,":[124],"7%":[126],"being":[127],"considered":[128],"critical":[129],"2%":[131],"leading":[132],"program":[134],"termination.":[135],"An":[136],"iterative,":[137],"weight-of-evidence":[138],"model":[139,157],"which":[140],"considers":[141],"factors":[142],"influence":[144],"overall":[146],"risk":[147],"cause":[152],"was":[154],"developed.":[155],"This":[156],"enables":[158],"an":[159],"evidence-based":[160],"justification,":[161],"suggesting":[162],"when":[163],"3-month":[164],"are":[167],"likely":[168],"sufficient":[169],"late-stage":[172],"clinical":[173],"some":[178]},"counts_by_year":[{"year":2026,"cited_by_count":15},{"year":2025,"cited_by_count":5},{"year":2024,"cited_by_count":12},{"year":2023,"cited_by_count":4}],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2023-01-06T00:00:00"}